BR112022008497A2 - Derivados terapêuticos da interleucina-22 - Google Patents

Derivados terapêuticos da interleucina-22

Info

Publication number
BR112022008497A2
BR112022008497A2 BR112022008497A BR112022008497A BR112022008497A2 BR 112022008497 A2 BR112022008497 A2 BR 112022008497A2 BR 112022008497 A BR112022008497 A BR 112022008497A BR 112022008497 A BR112022008497 A BR 112022008497A BR 112022008497 A2 BR112022008497 A2 BR 112022008497A2
Authority
BR
Brazil
Prior art keywords
interleukin
derivatives
therapeutic derivatives
therapeutic
therapy
Prior art date
Application number
BR112022008497A
Other languages
English (en)
Inventor
Sass-Ørum Kristian
Jørgensen Rasmus
Beck Jørgensen Sebastian
Thøgersen Henning
Hoeg-Jensen Thomas
Paolo Bastner SANDRINI Michael
Original Assignee
Cytoki Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoki Pharma Aps filed Critical Cytoki Pharma Aps
Publication of BR112022008497A2 publication Critical patent/BR112022008497A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

DERIVADOS TERAPÊUTICOS DA INTERLEUCINA-22. A invenção se refere a novos derivados de Interleucina-22 (IL-22), particularmente aqueles que compreendem um ácido graxo covalentemente ligado a uma proteína IL-22 e seu uso em terapia.
BR112022008497A 2019-11-07 2020-11-09 Derivados terapêuticos da interleucina-22 BR112022008497A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Publications (1)

Publication Number Publication Date
BR112022008497A2 true BR112022008497A2 (pt) 2022-07-26

Family

ID=68502950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008497A BR112022008497A2 (pt) 2019-11-07 2020-11-09 Derivados terapêuticos da interleucina-22

Country Status (15)

Country Link
US (3) US11806403B2 (pt)
EP (2) EP3819307A1 (pt)
JP (2) JP2023502005A (pt)
KR (1) KR20220097921A (pt)
CN (1) CN114761422A (pt)
AU (1) AU2020378648A1 (pt)
BR (1) BR112022008497A2 (pt)
CA (1) CA3160338A1 (pt)
CL (1) CL2022001185A1 (pt)
CO (1) CO2022005889A2 (pt)
CR (1) CR20220249A (pt)
IL (1) IL292657A (pt)
MX (1) MX2022005547A (pt)
PE (1) PE20221279A1 (pt)
WO (1) WO2021089875A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CN115955976A (zh) * 2020-04-17 2023-04-11 小利兰·斯坦福大学董事会 工程化白介素-22多肽及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (pt) 1964-12-21
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
BR112013015898A2 (pt) * 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
SG11201507429TA (en) 2013-03-15 2015-10-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
KR102302634B1 (ko) * 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
CN108348580B (zh) * 2015-07-15 2022-05-10 领导医疗有限公司 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
US20200181220A1 (en) * 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
PE20221279A1 (es) 2022-09-05
IL292657A (en) 2022-07-01
CA3160338A1 (en) 2021-05-14
CO2022005889A2 (es) 2022-07-29
CL2022001185A1 (es) 2023-02-03
US20240108731A1 (en) 2024-04-04
EP3819307A1 (en) 2021-05-12
JP2023083380A (ja) 2023-06-15
KR20220097921A (ko) 2022-07-08
US20220347304A1 (en) 2022-11-03
JP2023502005A (ja) 2023-01-20
US11806403B2 (en) 2023-11-07
CR20220249A (es) 2022-08-19
AU2020378648A1 (en) 2022-06-23
JP7479539B2 (ja) 2024-05-08
EP4055035A1 (en) 2022-09-14
CN114761422A (zh) 2022-07-15
WO2021089875A1 (en) 2021-05-14
MX2022005547A (es) 2022-07-04
US20230381320A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CO2022006030A2 (es) Inhibidores de ras
CL2023000974A1 (es) Inhibidores de ras
CO2020009625A2 (es) Inhibidor de fap
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
BR112022007163A2 (pt) Heterociclos bicíclicos como inibidores de fgfr
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
CO2021002386A2 (es) Métodos para la normalización del metabolismo de aminoácidos
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
BR112017011124A2 (pt) 1-[2-(aminometil)benzil]-2-tioxo-1,2,3,5-tetraidro-4h-pirrolo[3,2-d]pirimidin-4-ona como inibidor da mieloperoxidase
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
BR112021020496A2 (pt) Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
CL2023001556A1 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos